Can I Take CoQ10 with Low-Dose Naltrexone?

What You Actually Need to Know First

Low-dose naltrexone is prescribed off-label at doses between 1.5 mg and 4.5 mg, far below the 50 mg dose used for opioid or alcohol use disorder. At these micro-doses, LDN is thought to modulate immune function and reduce neuroinflammation rather than block opioid receptors continuously. Women make up the majority of people using LDN off-label, largely because the conditions it targets most often, fibromyalgia, multiple sclerosis, Hashimoto's thyroiditis, Crohn's disease, and PCOS-related inflammation, disproportionately affect women.

CoQ10 (coenzyme Q10, also called ubiquinone or ubiquinol) is a fat-soluble antioxidant your cells produce naturally and require for mitochondrial energy production. Tissue levels decline with age, statin use, and certain chronic conditions. Women approaching perimenopause often notice fatigue and reduced exercise tolerance that correlates temporally with falling CoQ10 and estrogen levels, which makes supplementation appealing.

The short answer: there is no documented direct interaction. The longer answer requires understanding what each compound does, where the theoretical pharmacodynamic overlap exists, and how your specific life stage and other medications change the picture.

How Low-Dose Naltrexone Works in Women

The Mechanism Behind LDN's Effects

Standard naltrexone competitively blocks mu-, delta-, and kappa-opioid receptors. At the micro-doses used in LDN therapy, transient receptor blockade for roughly four to six hours is followed by a rebound upregulation of endogenous opioids, primarily beta-endorphin and Met-enkephalin. This rebound is thought to reduce microglial activation and pro-inflammatory cytokine output, including TNF-alpha and IL-6.

LDN also appears to act on toll-like receptor 4 (TLR4) on microglia and macrophages, independent of opioid receptors. A 2013 pilot study in fibromyalgia (88% female participants) showed a 30% reduction in pain compared with placebo, providing some of the strongest sex-specific clinical evidence for LDN to date.

Hormonal Interactions Worth Knowing

Naltrexone is metabolized primarily by the liver via carbonyl reduction to 6-beta-naltrexol, with minor CYP3A4 involvement. Estrogen influences carbonyl reductase activity, which means your hormonal status could subtly affect how quickly you clear naltrexone. This has not been studied rigorously in women across different hormonal phases, and WomanRx flags this as a genuine evidence gap. What is known: naltrexone pharmacokinetics show roughly a two-fold variability in peak plasma concentration across individuals, and sex is one factor contributing to that spread.

Women in perimenopause and postmenopause may have altered liver enzyme activity alongside shifting estrogen, which could influence LDN clearance. No dosing adjustment is formally recommended, but if you notice heightened side effects (vivid dreams, nausea, or insomnia) around your cycle's luteal phase or during a hormonal dip, that timing is worth reporting to your prescriber.

How CoQ10 Works and Why Women Often Take It

Mitochondrial Energy and Antioxidant Roles

CoQ10 sits within the inner mitochondrial membrane as an electron carrier in the respiratory chain. It shuttles electrons between Complexes I/II and Complex III, and in its reduced form (ubiquinol), it also neutralizes free radicals. Tissue concentrations peak in the third decade of life and decline steadily thereafter.

The practical consequence for women: by the mid-40s, both CoQ10 synthesis and ovarian estrogen output are falling simultaneously. Estrogen itself has antioxidant properties and supports mitochondrial biogenesis. Losing it during perimenopause may amplify the functional impact of lower CoQ10.

Conditions in Women That Prompt CoQ10 Use

Women are prescribed or choose CoQ10 for several reasons that frequently overlap with LDN indications:

• Statin-induced myopathy. Statins deplete CoQ10 by blocking the mevalonate pathway. Women on statins for cardiovascular risk reduction report muscle pain at rates comparable to men, and CoQ10 supplementation at 200 mg/day has been studied as a potential mitigant, though trial results are mixed.
• PCOS and mitochondrial dysfunction. Women with PCOS show evidence of increased oxidative stress. A 2015 RCT found that CoQ10 at 180 mg/day improved insulin sensitivity and androgen markers in women with PCOS over 12 weeks.
• Fertility and egg quality. CoQ10 supplementation before IVF cycles is used to support oocyte mitochondrial function, with Fertility & Sterility data suggesting modest improvements in mature oocyte yield in women over 35, though effect sizes remain under debate.
• Migraine prevention. Migraine affects women three times more often than men. A Cochrane-adjacent systematic review found CoQ10 associated with reduced migraine frequency, relevant because migraine prevalence tracks with estrogen fluctuation across the cycle.
• Autoimmune fatigue. Women with lupus, MS, or Hashimoto's often report fatigue as their most disabling symptom. CoQ10 is frequently self-initiated alongside LDN in this group.

The Interaction Question: LDN + CoQ10 Side by Side

No controlled trial has directly studied the combination of LDN and CoQ10 in any population. The interaction analysis must therefore be built from mechanistic reasoning and indirect data. WomanRx structures this as a three-part framework:

1. Pharmacokinetic Interaction (Absorption, Distribution, Metabolism, Excretion)

Verdict: No meaningful pharmacokinetic interaction identified.

LDN undergoes hepatic carbonyl reduction and minimal CYP3A4 metabolism. CoQ10 is absorbed via intestinal lymphatic transport (chylomicron-dependent), distributed to lipid-rich tissues, and is not a meaningful inducer or inhibitor of CYP enzymes at supplemental doses. The two compounds do not compete for the same metabolic enzymes, transport proteins, or excretion pathways at clinically relevant concentrations.

CoQ10 bioavailability is fat-dependent, so taking it with a meal containing fat is sensible, but this has no bearing on LDN absorption. LDN is typically taken at bedtime on an empty stomach to align with the natural endorphin peak. You can take CoQ10 at any meal without concern for separating it from LDN by time.

2. Pharmacodynamic Interaction (Overlapping Effects on the Body)

Verdict: One theoretical interaction deserves attention, blood pressure.

CoQ10 has demonstrated modest antihypertensive effects. A meta-analysis of 12 clinical trials found mean reductions in systolic blood pressure of approximately 17 mmHg and diastolic of 10 mmHg with CoQ10 supplementation in hypertensive patients. LDN itself does not directly lower blood pressure, but the endorphin rebound it induces has vasodilatory properties through opioid receptor activity in vascular smooth muscle.

If you also take a calcium-channel blocker, ACE inhibitor, or ARB, adding CoQ10 to a regimen that already includes LDN could theoretically produce additive blood-pressure lowering. This matters most for women in perimenopause and postmenopause, where hypertension prevalence rises sharply after estrogen loss. The American Heart Association notes that women over 65 have higher rates of hypertension than men of the same age.

Practically: check your blood pressure at home for two weeks after starting or significantly increasing CoQ10 if you are also on antihypertensives. Dizziness or lightheadedness on standing warrants a same-week call to your prescriber.

3. Disease-Level Interaction (Do They Work Against Each Other or Together?)

Verdict: The mechanisms are complementary in the conditions most women take them for.

LDN reduces neuroinflammation via microglial modulation; CoQ10 reduces oxidative stress via mitochondrial electron transport stabilization. Both are relevant in fibromyalgia, Hashimoto's thyroiditis, MS-related fatigue, and PCOS-associated metabolic dysfunction. There is no evidence that CoQ10 diminishes LDN's anti-inflammatory effect or vice versa. Some integrative clinicians use them together intentionally, though this clinical practice has not been studied in a registered trial.

Dosing Considerations for Women at Different Life Stages

Reproductive Years (Ages 18 to 40)

LDN at 1.5 to 4.5 mg nightly is used off-label in this group for PCOS-related inflammation, Hashimoto's, and fibromyalgia. CoQ10 at 100 to 200 mg daily with a fat-containing meal is reasonable. Menstrual cycle tracking is worth doing when you start LDN, because endorphin fluctuations across the cycle mean LDN's effect profile may vary between the follicular and luteal phases. Some women report more vivid dreams or heavier sleep disturbance in the luteal phase on LDN.

Perimenopause (Typically Ages 40 to 52)

This is the life stage where both supplements and LDN use cluster most heavily for women. Falling estrogen amplifies the effects of lower CoQ10, and inflammation-driven conditions like autoimmune thyroiditis and fibromyalgia often flare during hormonal flux. The Menopause Society's 2023 position statement does not specifically address LDN, but acknowledges the importance of non-hormonal options for women who cannot or will not use menopausal hormone therapy.

CoQ10 at 200 to 300 mg daily (ubiquinol form preferred for women over 40 due to reduced conversion capacity) alongside LDN carries no identified risk at these doses. Blood pressure monitoring is more relevant here because hypertension incidence rises.

Postmenopause (Ages 52+)

Statin use increases in postmenopause for cardiovascular risk reduction. A woman who is postmenopausal, on a statin, taking LDN for an autoimmune condition, and supplementing CoQ10 to offset statin-induced myopathy is a common clinical picture. The statin adds a depletion rationale for CoQ10 that makes supplementation more evidence-grounded in this group. Statin-induced CoQ10 depletion is well-documented mechanistically, even if the clinical benefit of replenishment remains debated.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, breastfeeding, or trying to conceive.

LDN in Pregnancy

LDN is not recommended during pregnancy. Naltrexone is classified as FDA Pregnancy Category C, meaning animal studies have shown adverse fetal effects and adequate well-controlled studies in pregnant women are absent. A small observational case series described LDN use in women with Crohn's disease during pregnancy without apparent fetal harm, but this data is far too limited to support routine use. The opioid receptor system plays a documented role in fetal development, placental function, and labor onset, making theoretical risk real.

If you are trying to conceive, discuss a planned LDN pause with your prescriber before conception. If you become pregnant unexpectedly while on LDN, contact your prescriber within the week rather than stopping abruptly without guidance, since abrupt discontinuation is generally safe but your prescriber should know.

LDN During Lactation

Naltrexone does transfer into breast milk. Animal data show transfer, and the relative infant dose in humans has not been formally quantified for the low-dose formulation. Given the opioid receptor activity of even low-dose naltrexone in a developing infant, most women's-health clinicians recommend avoiding LDN while breastfeeding.

CoQ10 in Pregnancy and Lactation

CoQ10 has been studied in pregnancy specifically in the context of preeclampsia prevention. A randomized trial published in AJOG found that 200 mg/day of CoQ10 from 20 weeks reduced the risk of preeclampsia in high-risk women by approximately 44%, though this was a small trial (235 women) and has not been replicated at scale. CoQ10 is generally considered low-risk in pregnancy based on available data, but formal safety classification is limited. During lactation, CoQ10 is likely present in breast milk naturally, and supplemental doses have not been associated with infant harm in reported case experience.

Contraception

LDN does not interact with hormonal contraceptives in a clinically documented way. However, because LDN influences endorphin tone, women using hormonal contraception who add LDN sometimes report cycle-related mood changes. If you are using LDN for a condition that requires reliable contraception (not the case for naltrexone itself, unlike some other off-label drugs), discuss your method with your prescriber.

Who This Combination Is Right For and Who Should Be Cautious

Good Candidates

• Women with fibromyalgia, Hashimoto's thyroiditis, PCOS, or MS-related fatigue who are using LDN and want to address mitochondrial depletion or statin-related CoQ10 loss.
• Perimenopausal women with fatigue and inflammation who are not candidates for hormone therapy.
• Women on statins who use LDN and need CoQ10 for musculoskeletal support.

Exercise Extra Caution If You

• Take two or more antihypertensive agents. The additive blood-pressure-lowering effect of CoQ10 warrants closer monitoring.
• Are pregnant or planning pregnancy within the next three months. Pause this conversation with your prescriber before conception.
• Are breastfeeding. LDN is not the right choice during lactation for most women.
• Take warfarin. CoQ10 has a documented interaction with warfarin that can reduce its anticoagulant effect. This is a warfarin-CoQ10 interaction, not LDN-CoQ10, but it matters if you take all three.

What the Evidence Gap Looks Like

Women have been under-represented in pharmacokinetic drug trials for decades. The 2001 Government Accountability Office report documented systematic exclusion of women from clinical trials, and though regulatory requirements have improved, sex-stratified data on off-label drugs like LDN remains thin.

For this specific combination:

• No RCT exists for LDN plus CoQ10 in any population, let alone in women specifically.
• The fibromyalgia LDN trial Younger et al. (2013) enrolled predominantly women but did not assess concurrent supplements.
• CoQ10's effect on opioid receptor signaling has not been studied in humans.

What this means for you: the safety inference is built on mechanism, not on a trial that enrolled women like you. That is not a reason to avoid the combination, but it is a reason to track your own response systematically. Keep a brief symptom log for the first four weeks after adding CoQ10 to LDN: note energy, pain ratings on a 0-to-10 scale, blood pressure readings, and any sleep changes.

Practical Guidance: How to Take Both

| Factor | LDN | CoQ10 | |---|---|---| | Typical dose | 1.5 to 4.5 mg | 100 to 400 mg | | Timing | Bedtime, empty stomach | With largest fat-containing meal | | Form | Compounded capsule or liquid | Ubiquinol preferred over 40 | | Requires prescription | Yes (compounded) | No | | Blood pressure check | At baseline | After 2 weeks if on antihypertensives | | Pregnancy | Not recommended | Low risk, discuss with OB |

Take LDN at bedtime. Take CoQ10 with dinner or lunch, whichever contains more fat. There is no need to separate them by time; they simply work better with those independent conditions. Most women find a stable routine within two weeks. Report persistent nausea or dizziness to your prescriber; these symptoms are more likely attributable to LDN (the more pharmacologically active agent) than to CoQ10.